Research Papers:
Multicycle chemotherapy with the glycolipidlike polymeric micelles evade cancer stem cell enrichment in breast cancer therapy
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 2240 views | Full Text 2267 views
Tingting Meng1, Jingwen Liu1, Lijuan Wen1, Ming Yuan1, Bolin Cheng1, Yingwen Hu1, Yun Zhu1, Xuan Liu1, Hong Yuan1, Fuqiang Hu1
1Institute of Pharmaceutics, College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, China
Correspondence to:
Fuqiang Hu, email: [email protected]
Keywords: multi-cycle chemotherapy, tumor repopulation, drug delivery, cancer stem cell, microenvironment
Received: April 05, 2016 Accepted: September 13, 2016 Published: September 21, 2016
ABSTRACT
Multi-cycle chemotherapy is commonly used in the clinic, while the phenomena of enrichment of cancer stem cells (CSCs) and enhanced multi-drug resistance (MDR) are commonly involved. This research was designed for evaluating this successive administration. Chitosan oligosaccharide-g-stearic acid (CSOSA) polymer was used as the drug delivery system (DDS) to perform tri-cycle chemotherapy on a new tumor model induced by mammosphere cells. In vitro, on CSCs enriched mammospheres model, the doxorubicin-loaded CSOSA (CSOSA/DOX) displayed an improved growth inhibition effect measured by acid phosphatase assay (APH). While in vivo, the CSOSA/DOX micelles blocked tumor progression and led to a marked decrease of CSCs proportion as well as MDR capacity. What’s more, the CSOSA/DOX helped decay the microenvironment and attenuate systemic side effects. We concluded that the CSOSA polymer could be a potential DDS for long-term multi-cycle chemotherapy in antitumor research.